BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Beacon for rare diseases - ECPv6.10.3//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:Beacon for rare diseases X-ORIGINAL-URL:https://www.rarebeacon.org X-WR-CALDESC:Events for Beacon for rare diseases REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Europe/Paris BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20250330T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20251026T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250731T153000 DTEND;TZID=Europe/Paris:20250731T163000 DTSTAMP:20260428T153410 CREATED:20250714T102211Z LAST-MODIFIED:20250717T122050Z UID:61248-1753975800-1753979400@www.rarebeacon.org SUMMARY:Cures Within Reach new funding call: Clinical trials to validate AI-driven drug repurposing DESCRIPTION:Has an AI model identified a potential drug for your condition that’s ready to be validated in a clinical trial?\n \n \n \n \n \n Join our upcoming webinar exploring the latest Cures Within Reach funding opportunity – hosted in partnership with REMEDi4ALL and Cures Within Reach!\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Artificial intelligence (AI) is increasingly seen as a powerful tool in the search for new treatments – especially through drug repurposing. By analysing large sets of data\, AI can help identify existing medicines that might work for different conditions. \nThis is particularly valuable in rare diseases\, where repurposing offers a potentially faster\, more cost-effective path to finding treatment options. \nYou can read more about drug repurposing here. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n AI has shown promise in supporting this process\, but a key question remains:\n Do AI-generated predictions actually work when tested in real-life clinical trials?\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Cures Within Reach is helping to explore this question through a new funding call. \nThey’re inviting letters of intent for Phase I/IIA clinical trials that will test and validate AI-based repurposing ideas\, with a preference for rare disease. The aim is to build the evidence needed to validate and improve the AI models to help find treatments that work in real-world settings. \nYou can visit https://bit.ly/cwrrfps for more information. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n So what does this look like in practice\, and how can patient groups take part?\n \n \n \n \n \n Join us in this webinar to find out!\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Up to $100\,000 in funding is available for early-stage clinical trials (Phase I or IIA) that test existing drugs or therapies for new uses\, identified through AI models \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Additional funding is available to support community engagement alongside the trial \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Eligible trials must be based on AI-generated data that supports the repurposing idea \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n The call is open to any unsolved disease\, but there’s a strong preference for rare conditions and for using off-patent treatments \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n What will we cover in this webinar?\n \n \n \n \n \n \nA breakdown of what this funding call is about\nAdvice from Cures Within Reach on what makes a strong application\nHow patient groups can get involved in applications\nA practical example of a patient group contributing to an AI-led initiative\nThe opportunity to ask any questions you might have to the Cures Within Reach team\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Meet the speakers\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Clare Thibodeaux\, PhD is Vice President of Scientific Affairs at Cures Within Reach\, where she leads the organisation’s scientific initiatives and grant review processes. \nWith nearly 20 years of experience in research and philanthropy\, Clare works closely with researchers\, patient advocates\, and industry partners to drive forward clinical trials in drug repurposing. She also serves on the Advisory Board for the CURE Drug Repurposing Collaboratory and plays a key role in developing funding calls. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n CJ Wright serves as the Director\, Scientific Affairs at Cures Within Reach. He joined the team in 2024 after graduating from Purdue University with his PharmD. CJ has experience at large and small pharmaceutical companies\, academic health centers and regional hospitals and consulting companies. \nHe supports Cures Within Reach’s funding opportunities\, works with the Grant Review Committee\, manages post-award grants reporting and assists with other scientific initiatives. \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Who is this webinar for?\n  \nThis session is open to any patient group interested in learning more about this unique funding opportunity – including patient groups already involved in AI-driven clinical research\, as well as those looking to better understand how AI can support drug repurposing. \nNo technical AI experience is needed – the session is designed to be accessible regardless of where you are on your journey! \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Join this webinar to learn more about this funding call and how your patient group can contribute to a successful application! \n \n \n \n \n \n \n \n \n \n \n \n \n \n Register now\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Please note: the ticket window may take a few seconds to load.  \nTo secure your order\, please ensure you complete the form in its entirety. URL:https://www.rarebeacon.org/event/cwr-new-funding-call-validating-ai-models-in-drug-repurposing/ LOCATION:Online via Zoom CATEGORIES:Online,Webinar ATTACH;FMTTYPE=image/jpeg:https://www.rarebeacon.org/wp-content/uploads/2025/07/CWR-Funding-call-graphic-webinar-9.jpg ORGANIZER;CN="Beacon for Rare Diseases":MAILTO:projects@rarebeacon.org END:VEVENT END:VCALENDAR